EGFR and non-small cell lung carcinoma: Therefore, we conducted this multicenter, prospective observational study to investigate the details of rebiopsy, including the implementation or success rate of rebiopsy and the concordance rate for T790M mutation detection between histological and cytological specimens in EGFR-TKI-resistant NSCLC patients.